201 related articles for article (PubMed ID: 35989655)
21. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
22. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D
J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209
[TBL] [Abstract][Full Text] [Related]
24. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
25. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis.
Choi SH; Rim CH; Shin IS; Yoon WS; Koom WS; Seong J
Liver Cancer; 2021 Sep; 10(5):419-432. PubMed ID: 34721505
[TBL] [Abstract][Full Text] [Related]
27. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X
Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986
[TBL] [Abstract][Full Text] [Related]
28. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
29. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
30. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
Guo B; Tan X; Ke Q; Cen H
PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of immune checkpoint inhibitor as maintenance therapy for advanced or metastatic cancers: A meta-analysis of randomized controlled trials.
Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
Medicine (Baltimore); 2022 Sep; 101(38):e30830. PubMed ID: 36197237
[TBL] [Abstract][Full Text] [Related]
33. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis.
Poon I; Erler D; Dagan R; Redmond KJ; Foote M; Badellino S; Biswas T; Louie AV; Lee Y; Atenafu EG; Ricardi U; Sahgal A
JAMA Netw Open; 2020 Nov; 3(11):e2026312. PubMed ID: 33196810
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
[TBL] [Abstract][Full Text] [Related]
36. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
37. The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease.
Zeng Y; Ni J; Yu F; Zhou Y; Zhao Y; Li S; Guo T; Chu L; Yang X; Chu X; Cai X; Zhu Z
Radiat Oncol; 2020 Aug; 15(1):207. PubMed ID: 32854745
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
Breadner D; Blanchette P; Shanmuganathan S; Boldt RG; Raphael J
Lung Cancer; 2020 Jun; 144():57-63. PubMed ID: 32371261
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
